{
    "nct_id": "NCT03425279",
    "official_title": "A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors",
    "inclusion_criteria": "* Patients must have measurable disease.\n* Age ≥ 12 years (Phase 2)\n* Adequate renal function\n* Adequate liver function\n* Adequate hematological function\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of at least three months.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not have had major surgery within 4 weeks before first BA3011 administration.\n* Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.",
    "miscellaneous_criteria": ""
}